• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在活动期肢端肥大症患者中,与高铜蓝蛋白活性相关的氧化型低密度脂蛋白增加。

Increased oxidized low density lipoprotein associated with high ceruloplasmin activity in patients with active acromegaly.

机构信息

Department of Clinical Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET.

出版信息

Clin Endocrinol (Oxf). 2010 May;72(5):654-60. doi: 10.1111/j.1365-2265.2009.03685.x. Epub 2009 Aug 4.

DOI:10.1111/j.1365-2265.2009.03685.x
PMID:19681912
Abstract

OBJECTIVE

Active acromegaly is associated with increased mortality from cardiovascular causes. Several studies have shown increased atherogenic risk factors and biomarkers of inflammation and atherosclerosis in association with growth hormone excess. The aim of this study was to evaluate oxidized low density lipoprotein (oxLDL) levels and some modulators of LDL oxidative modification in patients with acromegaly.

DESIGN

Open transversal study.

PATIENTS

Fifteen patients with active acromegaly and 15 controls were studied.

MEASUREMENTS

We evaluated the levels of oxLDL, thiobarbituric acid reactive substances (TBARS), ceruloplasmin, bilirubin, uric acid and total reactive antioxidant potential, and the activities of ceruloplasmin, myeloperoxidase, superoxide distmutase, paraoxonase 1, and platelet activating factor acethylhydrolase. Statistical analysis was performed including body mass index as a covariate or as a fixed variable.

RESULTS

Patients with acromegaly showed significantly higher levels of oxLDL (120 +/- 19 vs. 86 +/- 20 U/l, P < 0.001) and endothelin (P < 0.05), increased ceruloplasmin activity (P < 0.01) and a trend towards higher values in TBARS concentration (P = 0.07) in comparison to healthy controls. OxLDL was positively associated with GH, IGF-I and its binding protein 3 (r = 0.63, P < 0.001; r = 0.53, P < 0.01; and r = 0.56, P < 0.01; respectively). OxLDL showed direct associations with endothelin-1 (r = 0.53, P < 0.01) and ceruloplasmin activity (r = 0.43, P < 0.05). The other parameters evaluated were similar in both groups.

CONCLUSIONS

The increase in plasma oxLDL levels, a direct marker of the plaque formation, could constitute a link between atherosclerosis and active acromegaly. LDL oxidation would not be the consequence of diminished antioxidant defences, but of an enhancement in prooxidant factors like ceruloplasmin.

摘要

目的

活性肢端肥大症与心血管原因导致的死亡率增加有关。几项研究表明,生长激素过多与动脉粥样硬化的致动脉粥样硬化风险因素和炎症生物标志物增加有关。本研究旨在评估患有肢端肥大症患者的氧化低密度脂蛋白(oxLDL)水平和一些 LDL 氧化修饰的调节剂。

设计

开放的横断研究。

患者

15 名患有活性肢端肥大症的患者和 15 名对照者接受了研究。

测量

我们评估了 oxLDL、硫代巴比妥酸反应物质(TBARS)、铜蓝蛋白、胆红素、尿酸和总反应性抗氧化能力,以及铜蓝蛋白、髓过氧化物酶、超氧化物歧化酶、对氧磷酶 1 和血小板激活因子乙酰水解酶的活性。进行了统计分析,包括体重指数作为协变量或固定变量。

结果

肢端肥大症患者的 oxLDL 水平(120 ± 19 比 86 ± 20 U/L,P < 0.001)和内皮素(P < 0.05)显著升高,铜蓝蛋白活性升高(P < 0.01),TBARS 浓度呈升高趋势(P = 0.07)与健康对照组相比。oxLDL 与 GH、IGF-I 和其结合蛋白 3 呈正相关(r = 0.63,P < 0.001;r = 0.53,P < 0.01;r = 0.56,P < 0.01)。oxLDL 与内皮素-1(r = 0.53,P < 0.01)和铜蓝蛋白活性(r = 0.43,P < 0.05)呈直接相关。两组的其他参数相似。

结论

血浆 oxLDL 水平的增加,斑块形成的直接标志物,可能是动脉粥样硬化和活性肢端肥大症之间的联系。LDL 氧化不是抗氧化防御减弱的结果,而是铜蓝蛋白等促氧化剂因素的增强。

相似文献

1
Increased oxidized low density lipoprotein associated with high ceruloplasmin activity in patients with active acromegaly.在活动期肢端肥大症患者中,与高铜蓝蛋白活性相关的氧化型低密度脂蛋白增加。
Clin Endocrinol (Oxf). 2010 May;72(5):654-60. doi: 10.1111/j.1365-2265.2009.03685.x. Epub 2009 Aug 4.
2
GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly.生长激素水平和胰岛素敏感性与活跃性肢端肥大症患者心血管疾病的生物标志物相关程度不同。
Clin Endocrinol (Oxf). 2012 Oct;77(4):579-85. doi: 10.1111/j.1365-2265.2012.04414.x.
3
Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly.活动性肢端肥大症中心血管疾病(CVD)生物标志物的改变。
Clin Endocrinol (Oxf). 2009 Jan;70(1):88-95. doi: 10.1111/j.1365-2265.2008.03323.x.
4
Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2.早期类风湿性关节炎患者表现出针对轻度氧化的低密度脂蛋白的自身抗体滴度升高,且脂蛋白相关磷脂酶A2的活性降低。
Arthritis Res Ther. 2007;9(1):R19. doi: 10.1186/ar2129.
5
[Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance].多囊卵巢综合征胰岛素抵抗患者血浆血小板活化因子乙酰水解酶的活性与分布
Zhonghua Fu Chan Ke Za Zhi. 2010 Jan;45(1):30-4.
6
Serum adiponectin levels in adult growth hormone deficiency and acromegaly.成人生长激素缺乏症和肢端肥大症患者的血清脂联素水平
Growth Horm IGF Res. 2004 Dec;14(6):449-54. doi: 10.1016/j.ghir.2004.06.005.
7
Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.成年生长激素缺乏症患者和肢端肥大症患者止血和纤维蛋白溶解标志物的改变。
Exp Clin Endocrinol Diabetes. 2000;108(7):486-92. doi: 10.1055/s-2000-8145.
8
Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?肢端肥大症生化缓解的临床指标:疾病控制不完全是否总是意味着治疗失败?
Clin Endocrinol (Oxf). 2005 Apr;62(4):410-7. doi: 10.1111/j.1365-2265.2005.02233.x.
9
HDL capacity to inhibit LDL oxidation in well-trained triathletes.训练有素的铁人三项运动员中高密度脂蛋白抑制低密度脂蛋白氧化的能力。
Life Sci. 2006 May 22;78(26):3074-81. doi: 10.1016/j.lfs.2005.12.015. Epub 2006 Feb 20.
10
Increased plasma endothelin level as an endothelial marker of cardiovascular risk in patients with active acromegaly: a comparison with plasma homocysteine.
Methods Find Exp Clin Pharmacol. 2009 Sep;31(7):457-61. doi: 10.1358/mf.2009.31.7.1406701.

引用本文的文献

1
The assessment of thiol-disulfide homeostasis and ıschemia-modified albumin levels in patients with acromegaly.肢端肥大症患者硫醇-二硫键稳态及缺血修饰白蛋白水平的评估。
Pituitary. 2025 Apr 5;28(2):46. doi: 10.1007/s11102-025-01519-y.
2
An Overview of Cardiovascular Risk in Pituitary Disorders.垂体疾病与心血管风险概述。
Medicina (Kaunas). 2024 Jul 30;60(8):1241. doi: 10.3390/medicina60081241.
3
Can signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) be used as an indicator of endothelial dysfunction in acromegaly patients?
信号肽-CUB-EGF 结构域蛋白 1(SCUBE-1)能否作为肢端肥大症患者内皮功能障碍的指标?
Endocrine. 2023 Oct;82(1):152-160. doi: 10.1007/s12020-023-03444-1. Epub 2023 Jul 14.
4
High chitotriosidase and AGE levels in acromegaly: a case-control study.肢端肥大症中几丁质酶和晚期糖基化终末产物水平升高:一项病例对照研究。
Hormones (Athens). 2023 Mar;22(1):61-69. doi: 10.1007/s42000-022-00409-3. Epub 2022 Oct 15.
5
Overdosing on iron: Elevated iron and degenerative brain disorders.铁过量:铁升高与退行性脑疾病。
Exp Biol Med (Maywood). 2020 Oct;245(16):1444-1473. doi: 10.1177/1535370220953065. Epub 2020 Sep 2.
6
Acromegaly, inflammation and cardiovascular disease: a review.肢端肥大症、炎症与心血管疾病:综述
Rev Endocr Metab Disord. 2020 Dec;21(4):547-568. doi: 10.1007/s11154-020-09560-x.
7
Determinants of morbidities and mortality in acromegaly.肢端肥大症中发病和死亡的决定因素。
Arch Endocrinol Metab. 2019 Nov-Dec;63(6):630-637. doi: 10.20945/2359-3997000000193.
8
The Endothelium in Acromegaly.肢端肥大症中的内皮细胞
Front Endocrinol (Lausanne). 2019 Jul 24;10:437. doi: 10.3389/fendo.2019.00437. eCollection 2019.
9
Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.肢端肥大症治疗后代谢参数和心血管危险因素的变化因治疗方式而异。来自比塞特尔队列的数据和文献复习。
Endocrine. 2019 Feb;63(2):348-360. doi: 10.1007/s12020-018-1797-8. Epub 2018 Nov 5.
10
Does Ceruloplasmin Defend Against Neurodegenerative Diseases?铜蓝蛋白能预防神经退行性疾病吗?
Curr Neuropharmacol. 2019;17(6):539-549. doi: 10.2174/1570159X16666180508113025.